Vanguard Capital Management
CORT icon

Vanguard Capital Management’s Corcept Therapeutics CORT Stock Holding History

Vanguard Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363M Buy
4,172,482
+95,286
+2% +$5.75M 0.01% 825
2026
Q1 		$164M Buy
+4,077,196
New +$152M ﹤0.01% 1192

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Vanguard Capital Management's CORT Position: Q2 2026 in Review

Vanguard Capital Management increased its Corcept Therapeutics (CORT) stake by 2.3% in Q2 2026, buying an estimated $5.75M and bringing the position to 4,172,482 shares worth $363M. The position accounts for 0.01% of the portfolio, ranked #825.

Vanguard Capital Management first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 415 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vanguard Capital Management held 4,172,482 shares of Corcept Therapeutics worth $363M as of Q2 2026.
  • Vanguard Capital Management bought 95,286 Corcept Therapeutics shares in Q2 2026, an estimated $5.75M.
  • Corcept Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #825 holding.
  • Vanguard Capital Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 415 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.